TMI-1 has been successfully used in mouse models of arthritis and kidney diseases to target and inhibit ADAM-17-mediated TNFα (Tumor Necrosis Factorα) and TGFα (Transforming Growth Factorα) release, respectively. Here, TGFA is linked to arthritic joint disease.